Inrebic (Fedratinib) for Myeloproliferative Neoplasms

Overview
Inrebic is a prescription drug approved by the U.S. Food and Drug Administration (FDA) to treat adults with intermediate or high-risk primary or secondary myelofibrosis, a cancer of the bone marrow. Inrebic is also referred to by its drug name, fedratinib.

Inrebic is a member of a class of drugs known as kinase inhibitors. It’s believed to work in cases of MPN by blocking the activity of a kinase enzyme known as JAK2, which is involved in cancer cell proliferation. Blocking JAK2 activity can result in cancer cell death.

How do I take it?
Prescribing information states that Inrebic is taken orally as a capsule once daily.
Do not stop taking Inrebic suddenly. If you decide to stop taking Inrebic, consult your physician for a plan to reduce your dose gradually. Inrebic should be taken exactly as prescribed by a physician.

Side effects
The FDA-approved label for Inrebic lists common side effects including diarrhea, nausea, vomiting, and low blood cell counts.

Rare but serious side effects listed for Inrebic include very low blood cell counts, encephalopathy (altered brain structure or function), gastrointestinal damage, liver damage, and high levels of certain pancreatic enzymes.

Inrebic might not be appropriate for people who are breastfeeding or have liver impairment. Inform your doctor of any existing medical conditions before taking Inrebic.

Call your doctor if you develop diarrhea, nausea, or vomiting that does not respond to treatment while taking Inrebic. Get emergency treatment immediately if you develop confusion, memory problems, or drowsiness; problems with balance and movement such as difficulty walking; or eye problems such as double or blurred vision or unusual eye movements.

For more details about this treatment, visit:

Inrebic homepage — Bristol Myers Squibb
https://www.inrebic.com/

Inrebic — Drugs.com
https://www.drugs.com/inrebic.html